Mahana Therapeutics Secures $61 Million Series B Financing To Support Commercialization And Further Development Of Digital Therapeutics
Aug 11, 2021•almost 4 years ago
Amount Raised
$61 Million
Round Type
series b
Description
Mahana Therapeutics, a leading developer of prescription digital therapeutics designed to empower patients with chronic health conditions, has completed a $61 million Series B financing. The company will use the funds to launch the FDA-cleared prescription digital therapeutic MahanaTM IBS and accelerate development of several digital therapeutics for chronic health conditions.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech